|Mr. David A. Ricks||Chairman, CEO & Pres||4.24M||N/A||1968|
|Dr. Daniel M. Skovronsky||Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs||2.14M||N/A||1974|
|Ms. Anat Hakim J.D.||Sr. VP, Gen. Counsel & Sec.||1.72M||N/A||1969|
|Mr. Alfonso G. Zulueta||Sr. VP & Pres of Lilly International||1.85M||N/A||1963|
|Ms. Anat Ashkenazi||Sr. VP & CFO||N/A||N/A||1973|
|Mr. Donald A. Zakrowski||Chief Accounting Officer & VP of Fin.||N/A||N/A||N/A|
|Mr. Martin Bott MIBS||VP of Fin. & Special Projects||N/A||N/A||1963|
|Mr. Diogo Rau||Sr. VP & Chief Information and Digital Officer||N/A||N/A||N/A|
|Kevin Hern||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Alonzo Weems||Sr. VP and Chief Ethics & Compliance Officer||N/A||N/A||N/A|
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; MiNA Therapeutics Limited; Verge Genomics; and The Banner Alzheimer's Institute, as well as Kumquat Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 4; Board: 10; Shareholder rights: 9; Compensation: 4.